Anxiety symptoms can influence sleep, recovery, pain, training consistency, work capacity, concentration, confidence, motivation and daily participation.
The GAD-2 was derived from the first two items of the GAD-7. It asks about two core anxiety symptoms: feeling nervous, anxious or on edge, and being unable to stop or control worrying.
Because it only has two items, the GAD-2 is often used as a quick first-step screening tool. A positive screen should usually lead to further assessment, such as completing the full GAD-7, clinical discussion or referral where appropriate.
The GAD-2 should be used within professional scope. Elevated scores should be handled sensitively and should not be treated as a diagnosis.
Outcome measure: Generalised Anxiety Disorder 2-item scale
Abbreviation: GAD-2
Category: Anxiety symptom screening questionnaire
Type: Self-report screening measure
Number of items: 2
Recall period: Previous two weeks
Score range: 0–6
Higher score means: Greater anxiety symptom frequency
Common cut-off: 3 or more out of 6
Best used for: Brief anxiety symptom screening
Key limitation: GAD-2 is not a diagnostic tool
The GAD-2 is a two-item screening questionnaire.
It asks how often, over the past two weeks, the person has been bothered by:
feeling nervous, anxious or on edge
not being able to stop or control worrying
Each item is scored from 0 to 3.
The total score ranges from 0 to 6.
A higher score indicates more frequent anxiety symptoms.
The GAD-2 is used because it provides a very quick way to screen for anxiety symptoms.
A client may report:
nervousness
worry
difficulty relaxing
sleep disruption
reduced concentration
reduced confidence
activity avoidance
increased tension
lower training consistency
difficulty managing life load
The GAD-2 may help professionals:
establish a quick baseline
identify whether further screening may be useful
support sensitive wellbeing conversations
monitor anxiety symptom change over time
decide whether the full GAD-7 may be appropriate
support referral-aware practice
consider how anxiety symptoms may interact with pain, sleep, recovery and participation
The score should be interpreted alongside client discussion, risk context, goals, sleep, workload, pain, function, support systems and professional judgement.
The GAD-2 measures the frequency of two anxiety symptoms over the previous two weeks.
It may provide insight into:
nervousness
anxiety
feeling on edge
uncontrollable worry
possible need for further assessment
anxiety symptom change over time
It does not directly measure:
diagnosis
full anxiety disorder criteria
panic symptoms
trauma symptoms
obsessive-compulsive symptoms
depression
suicide risk
cause of symptoms
work readiness
sport readiness
treatment need
The GAD-2 may be useful for:
wellbeing professionals
allied health support teams
rehabilitation practitioners working within scope
exercise professionals using referral-aware screening
movement assessment professionals
workplace wellbeing teams
students learning outcome measures
professionals monitoring distress alongside physical symptoms
It may be relevant for clients with:
persistent pain
sleep disruption
high stress
anxiety symptoms
reduced confidence
reduced recovery
fear of movement or reinjury
return-to-training concerns
high life load
reduced participation linked with worry or nervousness
Use the GAD-2 when you want a quick screen for anxiety symptoms over the past two weeks.
It may be useful at:
baseline wellbeing screening
initial assessment
progress review
persistent pain assessment
reassessment
return-to-training monitoring
workplace wellbeing review
referral-support discussion
The GAD-2 is especially useful when time is limited and a very brief screen is needed.
Use caution when:
the client is in crisis
suicide or self-harm concerns are present
distress is severe or rapidly worsening
the professional is not trained to respond appropriately
the score is being used as a diagnosis
the result is interpreted without discussion
language, literacy or cultural context affects responses
the client is younger than the intended population for the version used
The GAD-2 should not be used to:
diagnose generalised anxiety disorder
diagnose any anxiety disorder
assess suicide risk on its own
replace mental health assessment
replace medical assessment
determine treatment need on its own
clear someone for sport or work
replace professional judgement
If a client reports risk of harm, severe distress or safety concerns, follow the relevant referral, escalation or emergency process.
You need:
GAD-2 questionnaire
scoring instructions
baseline and retest dates
appropriate privacy and consent context
referral or escalation pathway if elevated scores or safety concerns occur
Optional related information may include:
GAD-7 if further anxiety screening is needed
PHQ-2 or PHQ-9 where mood screening is appropriate
sleep notes
pain ratings
fatigue ratings
workload notes
recovery notes
training exposure
relevant referral notes
Explain the purpose of the questionnaire before the client completes it.
Example wording:
“This short questionnaire asks about two common anxiety symptoms over the past two weeks. It does not diagnose an anxiety disorder, but it can help us decide whether further screening, support or referral may be useful.”
The GAD-2 can be completed:
on paper
digitally
independently
verbally if assistance is required
before a session
during reassessment
as part of wellbeing or progress monitoring
Ask the client to:
answer based on the past two weeks
choose how often each problem has bothered them
answer both items where possible
avoid overthinking each item
ask for clarification if they do not understand an item
complete the same version at retest
Each item is scored:
0 = Not at all
1 = Several days
2 = More than half the days
3 = Nearly every day
Add both items together.
Total score range:
0–6
Higher scores indicate greater anxiety symptom frequency.
A score of 3 or more is commonly used as a positive screening result.
Retest at meaningful time points, such as:
baseline
progress review
after a support period
after major workload or training change
after a symptom flare-up
follow-up monitoring
For consistency, record the same version, date, context over the past two weeks, sleep, workload, major life stressors and whether support or referral has changed.
The GAD-2 does not assess suicide risk directly.
If a client reports severe distress, risk of harm, crisis or safety concerns, do not rely on the GAD-2 alone. Follow appropriate referral, escalation or emergency procedures.
The GAD-2 total score ranges from 0 to 6.
Higher scores indicate more frequent anxiety symptoms over the previous two weeks.
Common interpretation:
0–2: lower likelihood of clinically significant anxiety symptoms
3–6: positive screen; further assessment may be warranted
A positive screen should usually lead to further assessment rather than a diagnostic label.
A higher GAD-2 score may suggest:
more frequent anxiety symptoms
more frequent worry
feeling nervous, anxious or on edge
possible need for further screening
value in completing the full GAD-7
possible referral or support discussion where appropriate
A high score does not diagnose anxiety.
A lower score may suggest fewer anxiety symptoms during the past two weeks.
A low score does not rule out anxiety concerns, especially if symptoms fluctuate, the client under-reports, or anxiety appears in situations not captured by the two items.
A GAD-2 score does not prove:
diagnosis
cause of anxiety symptoms
risk level
suicide risk status
treatment need
work readiness
sport readiness
whether one intervention caused the change
Example wording:
“Your GAD-2 score gives us a quick snapshot of anxiety symptoms over the past two weeks. It does not diagnose a condition, but it can help us decide whether further screening, support or referral may be useful.”
For general fitness clients, GAD-2 scores may help show whether worry or nervousness may be affecting motivation, sleep, exercise consistency or recovery.
For athletes, elevated scores may reflect competition pressure, injury concerns, performance anxiety, training stress, life load or broader mental health symptoms.
The score should not be used to determine sport readiness on its own.
For older adults, interpretation should consider general health, medication context, social support, sleep, pain, cognitive factors and life changes.
For youth clients, use age-appropriate screening processes and consider parent/guardian support, school context and referral pathways.
For persistent pain clients, the GAD-2 may help monitor anxiety symptoms that interact with pain, sleep, fatigue, movement confidence and participation.
For workplace populations, scores should be interpreted with consideration of workload, role demands, psychological safety, support and occupational health processes.
The GAD-2 is primarily a brief screening measure rather than a detailed progress outcome measure.
High-quality, universally applicable MCID or MDC values for every GAD-2 population are limited.
Change should be interpreted with:
baseline comparison
repeated measurement
discussion with the client
sleep and workload context
support or referral changes
pain and function changes
client goals
professional judgement
Because the GAD-2 has only two items, small score changes should be interpreted cautiously. When more detailed monitoring is needed, the full GAD-7 may be more useful.
The GAD-2 is generally interpreted using its score range and screening cut-off rather than broad normative values.
A score of 3 or more is commonly used as a positive screen.
However, performance may vary by:
population
age
language
culture
health context
pain status
pregnancy or postpartum context
work or study load
assessment setting
Practical comparison guidance:
compare the client with their own baseline
interpret the score with current context
use the cut-off as screening only
consider the full GAD-7 if further detail is needed
avoid treating a positive screen as a diagnosis
ensure referral pathways are available when needed
The GAD-2 has been widely studied as an ultra-brief anxiety screening measure.
It is derived from the first two items of the GAD-7 and has shown useful screening performance for generalised anxiety disorder and other anxiety disorders in primary care and other settings.
A commonly cited cut-off of 3 has been reported to provide a useful balance between sensitivity and specificity for identifying possible generalised anxiety disorder.
More recent systematic review evidence continues to support the GAD-2 and GAD-7 as commonly used anxiety screening measures, while also emphasising that screening tools do not replace diagnostic assessment.
Reliability and validity are strongest when:
the correct version is used
both items are completed
the client understands the timeframe
the score is interpreted as screening
elevated scores are followed by appropriate assessment or referral
results are interpreted within context
Interpret cautiously when:
the client is in crisis
language or culture affects responses
symptoms are complex or severe
the score is used without discussion
the result is used as a diagnosis
safety concerns are present
Common errors include:
treating GAD-2 as a diagnosis
using it without a referral pathway
ignoring severe distress or safety concerns
assuming a low score rules out anxiety
interpreting the score without discussion
using it to clear someone for sport or work
failing to follow up a positive screen
using it outside professional scope
Limitations include:
only two items
self-report can be influenced by willingness to disclose
it captures the past two weeks only
it does not assess suicide risk directly
it does not assess all anxiety disorders in detail
it does not assess depression, trauma or other concerns
cut-off performance varies by population
it should not replace mental health assessment where needed
The GAD-2 may help professionals:
quickly screen anxiety symptoms
document baseline worry and nervousness
decide whether the full GAD-7 may be useful
support referral-aware conversations
monitor broad change over time
understand how anxiety symptoms may interact with pain, sleep and training
improve whole-person assessment reasoning
For persistent pain and rehabilitation contexts, the GAD-2 can help identify whether anxiety symptoms may be interacting with pain, activity tolerance or participation.
For sport and workplace contexts, it can support screening and monitoring, but results should be handled confidentially and within appropriate professional boundaries.
The GAD-2 measures two anxiety symptoms over the past two weeks: feeling nervous, anxious or on edge, and not being able to stop or control worrying.
The GAD-2 has 2 items.
Each item is scored from 0 to 3. The total score ranges from 0 to 6.
A score of 3 or more is commonly used as a positive screening result.
No. The GAD-2 is a screening tool and does not diagnose anxiety disorders on its own.
A positive screen may support further assessment, such as completing the GAD-7, discussing symptoms further or considering referral where appropriate.
No. The GAD-2 does not directly assess suicide risk. Safety concerns require appropriate assessment and escalation.
It can be used for broad monitoring, but the full GAD-7 may be more useful when detailed anxiety symptom tracking is needed.
GAD-2 is a 2-item anxiety symptom screening questionnaire.
It asks about symptoms over the past two weeks.
Scores range from 0 to 6.
A score of 3 or more is commonly used as a positive screen.
GAD-2 does not diagnose anxiety disorders.
It does not assess suicide risk directly.
Elevated scores should be handled sensitively and within professional scope.
Interpretation is strongest when combined with discussion, context, support pathways and professional judgement.
Kroenke, K., Spitzer, R. L., Williams, J. B. W., Monahan, P. O., & Löwe, B. (2007). Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Annals of Internal Medicine, 146(5), 317–325. https://doi.org/10.7326/0003-4819-146-5-200703060-00004
National Collaborating Centre for Mental Health. (2011). Common mental health disorders: Identification and pathways to care. National Institute for Health and Care Excellence. Appendix 13: Generalized Anxiety Disorder Scale (2 items) Questionnaire. https://www.ncbi.nlm.nih.gov/books/NBK92248/
Plummer, F., Manea, L., Trepel, D., & McMillan, D. (2016). Screening for anxiety disorders with the GAD-7 and GAD-2: A systematic review and diagnostic meta-analysis. General Hospital Psychiatry, 39, 24–31. https://doi.org/10.1016/j.genhosppsych.2015.11.005
Sapra, A., Bhandari, P., Sharma, S., Chanpura, T., & Lopp, L. (2020). Using Generalized Anxiety Disorder-2 (GAD-2) and GAD-7 in a primary care setting. Cureus, 12(5), e8224. https://doi.org/10.7759/cureus.8224
